Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.59 |
| ▸ | RAF1 | P04049 | 4/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213009 | 0.87 | SRC (0.69) | SRCMAP2K1RAF1MAPK13MAP3K8 | |
| SCHEMBL3229498 | 0.83 | MAP2K1 (0.67) | SRCMAP2K1RAF1MAPK13MAP3K8 | |
| SCHEMBL7248239 | 0.81 | SRC (0.57) | SRCMAP2K1RAF1MAPK3MAPK1 | |
| SCHEMBL3229392 | 0.81 | MAP2K1 (0.69) | SRCMAP2K1RAF1MAPK13MAP3K8 | |
| SCHEMBL3233818 | 0.81 | SRC (0.66) | SRCMAP2K1RAF1MAPK13MAP3K8 | |
| SCHEMBL3234414 | 0.81 | SRC (0.57) | SRCMAP2K1RAF1MAPK13MAP3K8 | |
| SCHEMBL3229261 | 0.80 | SRC (0.63) | SRCMAP2K1RAF1MAPK13MAP3K8 | |
| SCHEMBL3216543 | 0.79 | SRC (0.55) | SRCMAP2K1RAF1MAPK3MAPK1 | |
| SCHEMBL3234087 | 0.79 | SRC (0.70) | SRCMAP2K1RAF1FYN | |
| SCHEMBL3223786 | 0.79 | SRC (0.62) | SRCMAP2K1RAF1EGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | SRC 237/4885MAP2K1 568/4885RAF1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.